Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 20 March, 2020

JPMorgan Asset Mngt

AbbVie Inc. 8.3

RNS Number : 0368H
JPMorgan Asset Management
20 March 2020
 

Ap19

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

Companydealtin

AbbVie Inc.

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

US$0.01 common stock

Date of dealing

19 March 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)


Long

Short


Number


(%)

Number


(%)

(1)Relevantsecurities

20,051,880*  1.35

3,126  0.00

(2) Derivatives (other than options)

15,347   0.00

 305,276  0.02

(3)Optionsandagreementstopurchase/sell



Total

20,067,227*  1.35

308,402  0.02

 

*In addition to the dealings in section 2a, there is an increase in the holding of 5 common stock due to a transfer.

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

Classofrelevantsecurity:

Long

Short


Number


(%)

Number


(%)

(1)Relevantsecurities



 

(2) Derivatives (other than options)



 

(3)Optionsandagreementstopurchase/sell



Total




Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

 

Purchase/sale

 

Numberofrelevantsecurities

 

Priceperunit (Note 5)

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

 

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

16

112

580

6

3,253

1,215

190,660

497

307,088

5,500

262

12,500

28,400

105,463

 

1,363

358

102

412

85,524

680

1,148

256,400

163

11

5

2

206

70.8675 USD

70.8676 USD

70.8677 USD

70.8683 USD

71.0300 USD

71.0600 USD

71.8069 USD

72.0456 USD

72.1635 USD

73.1650 USD

73.1715 USD

73.4791 USD

73.5643 USD

73.7279 USD

 

67.6094 USD

67.6098 USD

67.8000 USD

67.8107 USD

68.1968 USD

68.4799 USD

68.6718 USD

69.0954 USD

71.0600 USD

72.6670 USD

72.6680 USD

72.6700 USD

73.3354 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit

(Note 5)





 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)








 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)




 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)





Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)    NO

 

Dateofdisclosure

20 March 2020

Contact name

Daniel Swart

Telephone number

0207 134 6168

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

Allergan plc

If aconnectedEFM,statenatureofconnection (Note 10)

Financial Advisor to Allergan plc

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFLFFFVSIIFII

a d v e r t i s e m e n t